Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

.

Alexion Pharmaceuticals

(

ALXN

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.6%. By the end of trading, Alexion Pharmaceuticals rose $1.61 (1.5%) to $107.21 on light volume. Throughout the day, 903,729 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.4 million shares. The stock ranged in a price between $105.03-$107.49 after having opened the day at $106.53 as compared to the previous trading day's close of $105.60. Other companies within the Drugs industry that increased today were:

Neuralstem

(

CUR

), up 15.9%,

Idera Pharmaceuticals

(

IDRA

), up 14.3%,

Hemispherx Biopharma

(

HEB

), up 12.3%, and

StemCells

(

STEM

), up 10.7%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Alexion Pharmaceuticals has a market cap of $20.57 billion and is part of the

health care

sector. The company has a P/E ratio of 105.5, below the average drugs industry P/E ratio of 106.6 and above the S&P 500 P/E ratio of 17.7. Shares are up 49% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now

.

null